TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26355172

Group type: EXPERIMENTAL
Intervention: 1-drill group
Number of subjects: 40

Group type: COMPARATOR
Intervention: multiple-drill group
Number of subjects: 40
Study: 23398859

Group type: EXPERIMENTAL
Intervention: Tampon use (two types of tampons)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Pad use
Number of subjects: 7
Study: 21178123

Group type: EXPERIMENTAL
Intervention: Glycerol mixed with cranberry juice (97 ± 3 ml glycerol + equal portion of cranberry juice; n = 9)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo control (water + cranberry juice; n = 7)
Number of subjects: 16
Study: 18778333

Group type: EXPERIMENTAL
Intervention: Moxaverine (150 mg, administered i.v.)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 17359649

Group type: EXPERIMENTAL
Intervention: Real acupuncture
Number of subjects: 41

Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 41
Study: 15240597

Group type: EXPERIMENTAL
Intervention: Nutropin Depot 0.75 mg/kg once per month
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Nutropin Depot 0.75 mg/kg twice per month
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Nutropin Depot 1.5 mg/kg once per month
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Nutropin Depot (all dosing regimens)
Number of subjects: 138
Study: 12234957

Group type: EXPERIMENTAL
Intervention: Phase-velocity MRI (PV-MRI)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Lung perfusion scintigraphy
Number of subjects: 15
Study: 9722130

Group type: EXPERIMENTAL
Intervention: Tamoxifen 20 mg/day for 10 consecutive days starting on the 13th day of the menstrual cycle
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 24
Study: 8002320

Group type: EXPERIMENTAL
Intervention: Fluoxetine (20 mg, increased to 40 mg based on response)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Placebo (identical to fluoxetine)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 122

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 122
Study: 3404502

Group type: EXPERIMENTAL
Intervention: Placebo ultrasound
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Dentist-administered ultrasound
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Self-applied facial massage
Number of subjects: 79

Group type: COMPARATOR
Intervention: Untreated controls
Number of subjects: 79
Study: 31544925

Group type: EXPERIMENTAL
Intervention: Nurse-led care
Number of subjects: 1375

Group type: COMPARATOR
Intervention: Usual-care
Number of subjects: 1375

Group type: EXPERIMENTAL
Intervention: Nurse-led care (experienced centres)
Number of subjects: 1375

Group type: EXPERIMENTAL
Intervention: Nurse-led care (less experienced centres)
Number of subjects: 1375
Study: 29735469

Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Number of subjects: 0
Study: 27560168

Group type: EXPERIMENTAL
Intervention: pioglitazone (30 mg for 4 weeks, then 45 mg for 8 weeks)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: pioglitazone
Number of subjects: 68

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 68
Study: 25720332

Group type: EXPERIMENTAL
Intervention: Intraaortic balloon pump (IABP) support
Number of subjects: 41

Group type: COMPARATOR
Intervention: No IABP support (Control)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Microvascular perfusion
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Microcirculatory parameters
Number of subjects: 41
Study: 23561603

Group type: EXPERIMENTAL
Intervention: Trypan blue (TB)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Indocyanine green (ICG)
Number of subjects: 25
Study: 20598974

Group type: EXPERIMENTAL
Intervention: Elinogrel (intravenous and oral formulations)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 0
Study: 19133491

Group type: EXPERIMENTAL
Intervention: Mirtazapine (Remeron)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Serotonin reuptake inhibitors
Number of subjects: 0

Group type: COMPARATOR
Intervention: Venlafaxine (Effexor)
Number of subjects: 0
Study: 16374157

Group type: EXPERIMENTAL
Intervention: Nonbronchoscopic lavage
Number of subjects: 41

Group type: COMPARATOR
Intervention: Bronchoscopic lavage
Number of subjects: 41
Study: 12824830

Group type: EXPERIMENTAL
Intervention: Green argon laser photocoagulation for soft drusen
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Before macular atrophy development
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: After the appearance of macular atrophy
Number of subjects: 52
Study: 11136293

Group type: EXPERIMENTAL
Intervention: 30 mg microencapsulated octreotide acetate intramuscularly
Number of subjects: 0
Study: 8799516

Group type: EXPERIMENTAL
Intervention: Intravenous phylloquinone (vitamin K1) mixed micelles formulation (Konakion MM)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Intramuscular phylloquinone (vitamin K1) mixed micelles formulation (Konakion MM)
Number of subjects: 30
Study: 1629383

Group type: EXPERIMENTAL
Intervention: Alprazolam (average maximum dosage 2.2 mg)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Imipramine (average maximum dosage 97.5 mg)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 6483520

Group type: EXPERIMENTAL
Intervention: Slow-release theophylline sprinkle preparation (fasting)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Slow-release theophylline sprinkle preparation (after standardized meal)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Intravenous theophylline
Number of subjects: 12
Study: 29537451

Group type: EXPERIMENTAL
Intervention: Sarecycline 1.5 mg/kg
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: Sarecycline 3.0 mg/kg
Number of subjects: 285

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 285
Study: 28139568

Group type: EXPERIMENTAL
Intervention: Combined chemoradiotherapy (CRT) with 75 mg/m2 temozolomide (TMZ) followed by 200 mg/m2 TMZ for 5 days every 28 days
Number of subjects: 107

Group type: COMPARATOR
Intervention: Alternative treatments
Number of subjects: 107
Study: 24907874

Group type: EXPERIMENTAL
Intervention: O293 (oxygen from concentrators)
Number of subjects: 60

Group type: COMPARATOR
Intervention: O293N2O (oxygen from concentrators and nitrous oxide)
Number of subjects: 60
Study: 22414228

Group type: EXPERIMENTAL
Intervention: Repaglinide treatment for 8 weeks
Number of subjects: 367
Study: 20039413

Group type: EXPERIMENTAL
Intervention: Rituximab (1,000 mg) administered on days 1, 15, 168, and 182
Number of subjects: 257

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 257
Study: 18385912

Group type: EXPERIMENTAL
Intervention: Vardenafil (10 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 16037151

Group type: EXPERIMENTAL
Intervention: Sevoflurane (S)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Desflurane (D)
Number of subjects: 31
Study: 14577063

Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Randomized trials
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Nonrandomized studies
Number of subjects: 131
Study: 10894282

Group type: EXPERIMENTAL
Intervention: Ritonavir 400 mg twice daily plus Indinavir 400 mg twice daily with either Zidovudine/Lamivudine (49%), Stavudine/Lamivudine (38%), or Stavudine/Didanosine (13%)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Ritonavir 400 mg twice daily plus Indinavir 400 mg twice daily
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Ritonavir/Indinavir plus double nucleoside therapy
Number of subjects: 90
Study: 8669994

Group type: EXPERIMENTAL
Intervention: Back school program (3 sessions of 90 minutes each at 0, 1, and 8 weeks)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Standard treatment program (daily physiotherapy)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Back school program
Number of subjects: 168

Group type: COMPARATOR
Intervention: Standard treatment program
Number of subjects: 168
Study: 1508127

Group type: EXPERIMENTAL
Intervention: Flurbiprofen 300 mg/day, orally, starting the day before surgery and continuing for 7 consecutive days
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned in the abstract)
Number of subjects: 50
Study: 6308755

Group type: EXPERIMENTAL
Intervention: Pivmecillinam-pivampicillin (PMPA) 200 + 250 mg b.i.d.
Number of subjects: 67

Group type: COMPARATOR
Intervention: Pivmecillinam (PM) 400 mg b.i.d.
Number of subjects: 67
Study: 31974708

Group type: EXPERIMENTAL
Intervention: Postoperative chemotherapy (POCT)
Number of subjects: 582

Group type: COMPARATOR
Intervention: Surgery alone (Control)
Number of subjects: 582
Study: 29241383

Group type: COMPARATOR
Intervention: 600 µg buccal misoprostol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1000 mg oral TA plus 600 µg buccal misoprostol
Number of subjects: 0

Group type: COMPARATOR
Intervention: 10 IU oxytocin IV
Number of subjects: 0
Study: 29710132

Group type: EXPERIMENTAL
Intervention: Music festival visit for 4.5 hours
Number of subjects: 51

Group type: COMPARATOR
Intervention: Earplug use
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Quantity of alcohol use
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Drug use
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Male sex
Number of subjects: 51

Group type: COMPARATOR
Intervention: Earplug group
Number of subjects: 51
Study: 26829348

Group type: EXPERIMENTAL
Intervention: Valve Catheter (VC)
Number of subjects: 49
Study: 24619189

Group type: EXPERIMENTAL
Intervention: PTNS (n = 16)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control (n = 17)
Number of subjects: 33
Study: 21927922

Group type: EXPERIMENTAL
Intervention: Denosumab (60 mg every 6 months)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Alendronate (70 mg once weekly)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Denosumab after alendronate
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Alendronate after denosumab
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Denosumab
Number of subjects: 250
Study: 21029199

Group type: EXPERIMENTAL
Intervention: Post-game performance
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Fatigue index
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: High-intensity running
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Muscle temperature
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Net fluid loss
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Correlations
Number of subjects: 20
Study: 21124684

Group type: EXPERIMENTAL
Intervention: Endoscopic carpal tunnel release (CTR)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Open carpal tunnel release (CTR)
Number of subjects: 61
Study: 15857102

Group type: EXPERIMENTAL
Intervention: 1.50 mg/ml rhBMP‐2/ACS
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 0.75 mg/ml rhBMP‐2/ACS
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo (ACS alone)
Number of subjects: 80

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 80
Study: 12183244

Group type: EXPERIMENTAL
Intervention: Ertapenem (1 g once a day)
Number of subjects: 592

Group type: COMPARATOR
Intervention: Ceftriaxone (1 g daily)
Number of subjects: 592

Group type: EXPERIMENTAL
Intervention: Ertapenem and Ceftriaxone
Number of subjects: 592
Study: 10968433

Group type: EXPERIMENTAL
Intervention: Omapatrilat (40 mg daily for 24 weeks)
Number of subjects: 573

Group type: COMPARATOR
Intervention: Lisinopril (20 mg daily for 24 weeks)
Number of subjects: 573

Group type: EXPERIMENTAL
Intervention: Omapatrilat
Number of subjects: 573
Study: 8980437

Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy with transient carotid clamping
Number of subjects: 24
Study: 1453199

Group type: EXPERIMENTAL
Intervention: ALTER regimen
Number of subjects: 533

Group type: EXPERIMENTAL
Intervention: Maintenance Tam
Number of subjects: 533

Group type: COMPARATOR
Intervention: CMFPT
Number of subjects: 533

Group type: EXPERIMENTAL
Intervention: Continuing Tam
Number of subjects: 533

Group type: EXPERIMENTAL
Intervention: Development of amenorrhea
Number of subjects: 533

Group type: EXPERIMENTAL
Intervention: Decreasing nodal involvement and ER+ status
Number of subjects: 533

Group type: EXPERIMENTAL
Intervention: Progesterone receptor-positive (PgR+) status and decreasing tumor size
Number of subjects: 533

Group type: COMPARATOR
Intervention: Toxicity
Number of subjects: 533
Study: 4095819

Group type: EXPERIMENTAL
Intervention: Dietary advice (low-sucrose, low-fat, high-fiber, energy-restricted) and exercise (individual or group) for 6 months
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Glipizide, 1.25 mg daily added at breakfast for 10 subjects after 6 months of dietary and exercise treatment
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (18 GI subjects) with no treatment for 5-10 months
Number of subjects: 25
Study: 30883942

Group type: EXPERIMENTAL
Intervention: rhBMP‐2‐soaked absorbable collagen sponge (test group)
Number of subjects: 64

Group type: COMPARATOR
Intervention: β‐tricalcium phosphate and hydroxyapatite particles immersed in rhBMP‐2 (control group)
Number of subjects: 64
Study: 27634838

Group type: EXPERIMENTAL
Intervention: 12-week behavioral nutrition intervention
Number of subjects: 50

Group type: COMPARATOR
Intervention: Physical activity intervention
Number of subjects: 50
Study: 26990598

Group type: EXPERIMENTAL
Intervention: Fixed schedule financial incentives
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Escalating schedule financial incentives
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 24784894

Group type: EXPERIMENTAL
Intervention: Tadalafil 5 mg once-a-day
Number of subjects: 770

Group type: EXPERIMENTAL
Intervention: Tadalafil 10 mg on demand
Number of subjects: 770

Group type: COMPARATOR
Intervention: Sildenafil 50 mg on demand
Number of subjects: 770
Study: 22307061

Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiation (CCRT) with adjuvant chemotherapy (Paclitaxel 135 mg/m² + Cisplatin 75 mg/m²)
Number of subjects: 880

Group type: COMPARATOR
Intervention: Concurrent chemoradiation (CCRT) alone
Number of subjects: 880
Study: 19957087

Group type: EXPERIMENTAL
Intervention: PETN 80 mg t.i.d.
Number of subjects: 80

Group type: COMPARATOR
Intervention: C
Number of subjects: 80
Study: 17335950

Group type: EXPERIMENTAL
Intervention: Imagery training group
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (passively observing the task)
Number of subjects: 20
Study: 15766834

Group type: EXPERIMENTAL
Intervention: Bare-metal stent (BMS)
Number of subjects: 2512

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stent (SES)
Number of subjects: 2512

Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stent (PES)
Number of subjects: 2512
Study: 12021739

Group type: EXPERIMENTAL
Intervention: High-intensity treadmill exercise at 75% O(2max) with placebo
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Low-intensity exercise at 40% O(2max) with placebo
Number of subjects: 6

Group type: COMPARATOR
Intervention: Naloxone treatment (10 mg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: No exercise control (placebo or naloxone)
Number of subjects: 6
Study: 10448452

Group type: EXPERIMENTAL
Intervention: Interactive group psychoeducation
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control therapy
Number of subjects: 57
Study: 8641319

Group type: EXPERIMENTAL
Intervention: Iloprost (0.7 ng x kg x min(‐1))
Number of subjects: 14
Study: 2086017

Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Aspirin 20mg/d
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Diltiazem plus Aspirin
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (Placebo)
Number of subjects: 60
Study: 31065992

Group type: EXPERIMENTAL
Intervention: Oxycodone ARIR 30 mg under fasted conditions
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Oxycodone ARIR 30 mg under fed conditions
Number of subjects: 58

Group type: COMPARATOR
Intervention: IR oxycodone 30 mg under fasted conditions
Number of subjects: 58
Study: 28470952

Group type: EXPERIMENTAL
Intervention: tolvaptan
Number of subjects: 1445
Study: 25229335

Group type: EXPERIMENTAL
Intervention: Intensive glycemic control
Number of subjects: 3636

Group type: COMPARATOR
Intervention: Standard glycemic control
Number of subjects: 3636
Study: 23084077

Group type: EXPERIMENTAL
Intervention: Lutein-based oral supplement
Number of subjects: 14

Group type: COMPARATOR
Intervention: No supplement (non-treated group)
Number of subjects: 14
Study: 21617091

Group type: EXPERIMENTAL
Intervention: Multifaceted nurse/nephrologist-supported care
Number of subjects: 474

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 474
Study: 19625036

Group type: EXPERIMENTAL
Intervention: Multimedia version of the American Urological Association symptom score
Number of subjects: 232

Group type: COMPARATOR
Intervention: Traditional written version of the American Urological Association symptom score
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Multimedia version for patients with low literacy
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Multimedia version for patients with high literacy
Number of subjects: 232
Study: 16908788

Group type: EXPERIMENTAL
Intervention: Varenicline tartrate 1.0 mg twice daily
Number of subjects: 638

Group type: EXPERIMENTAL
Intervention: Varenicline tartrate 1.0 mg once daily
Number of subjects: 638

Group type: EXPERIMENTAL
Intervention: Bupropion hydrochloride 150 mg twice daily
Number of subjects: 638

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 638
Study: 15243882

Group type: EXPERIMENTAL
Intervention: RFSNN technique for detecting H. pylori infection
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: RFSNN technique for predicting gastric histological features
Number of subjects: 104
Study: 11558289

Group type: EXPERIMENTAL
Intervention: CEA with primary closure
Number of subjects: 510

Group type: EXPERIMENTAL
Intervention: CEA with patching (PTFE or vein patch closure)
Number of subjects: 510

Group type: EXPERIMENTAL
Intervention: Patching using PTFE or vein patch closure
Number of subjects: 510

Group type: EXPERIMENTAL
Intervention: Primary closure
Number of subjects: 510

Group type: EXPERIMENTAL
Intervention: Hemashield patch
Number of subjects: 510
Study: 9161395

Group type: EXPERIMENTAL
Intervention: Early feeding (EF group, n = 29)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Traditional feeding (TF group, n = 29)
Number of subjects: 58
Study: 8194142

Group type: EXPERIMENTAL
Intervention: NIDDM patients
Number of subjects: 498

Group type: COMPARATOR
Intervention: Non-diabetic controls
Number of subjects: 498

Group type: EXPERIMENTAL
Intervention: NIDDM patients with hyperlipidaemia
Number of subjects: 498

Group type: EXPERIMENTAL
Intervention: NIDDM patients with normolipidaemia
Number of subjects: 498
Study: 3538964

Group type: EXPERIMENTAL
Intervention: Health Maintenance Organization (HMO)
Number of subjects: 1522

Group type: COMPARATOR
Intervention: Fee-for-Service System
Number of subjects: 1522
Study: 29061382

Group type: EXPERIMENTAL
Intervention: Daily meal distribution approach
Number of subjects: 206

Group type: COMPARATOR
Intervention: Food voucher intervention
Number of subjects: 206
Study: 27214055

Group type: EXPERIMENTAL
Intervention: Guided Imagery (GI)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo-Control (audiobook segments)
Number of subjects: 82
Study: 24665971

Group type: EXPERIMENTAL
Intervention: 500 μg F/g with 1% TMP
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: 500 μg F/g with 0.25% CaGP
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: 1100 μg F/g
Number of subjects: 56
Study: 23015748

Group type: EXPERIMENTAL
Intervention: Adjunctive antidepressant treatment
Number of subjects: 376

Group type: EXPERIMENTAL
Intervention: Previous episodes categorized as less than 5, 5‐10, and more than 10
Number of subjects: 376
Study: 20823381

Group type: EXPERIMENTAL
Intervention: Achieved on‐treatment systolic BP levels in the first 24 hours
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: Intensive BP reduction to systolic levels between 130 and 140 mm Hg
Number of subjects: 404

Group type: COMPARATOR
Intervention: Baseline systolic BP levels
Number of subjects: 404
Study: 18491071

Group type: EXPERIMENTAL
Intervention: Fish oil (daily docosahexaenoic/eicosapentaenoic acid capsules, no other seafood; single-blinded)
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: Lean fish (150 g cod, three times/week)
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: Fatty fish (150 g salmon, three times/week)
Number of subjects: 324

Group type: COMPARATOR
Intervention: Control (no seafood; single-blinded)
Number of subjects: 324
Study: 16895641

Group type: EXPERIMENTAL
Intervention: Early Cleavage Assessment (ECA)
Number of subjects: 196

Group type: COMPARATOR
Intervention: Early Cleavage Not Assessed (ECNA)
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Both groups (ECA and ECNA)
Number of subjects: 196
Study: 12970007

Group type: EXPERIMENTAL
Intervention: Nebulized levalbuterol, 1.25 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Racemic albuterol, 2.5 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Combined racemic albuterol, 2.5 mg, and ipratropium, 0.5 mg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 10381159

Group type: EXPERIMENTAL
Intervention: Test diet (increased vegetable protein and soluble fiber)
Number of subjects: 31
Study: 8678103

Group type: EXPERIMENTAL
Intervention: Cefepime (1 g every 12 hours)
Number of subjects: 298

Group type: COMPARATOR
Intervention: Ceftazidime (1 g every 8 hours)
Number of subjects: 298
Study: 1906097

Group type: EXPERIMENTAL
Intervention: Cefixime (8 mg/kg daily)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Amoxicillin (40 mg/kg daily)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Cefixime and Amoxicillin
Number of subjects: 126
Study: 6134671

Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pindolol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Labetalol
Number of subjects: 0
Study: 29878103

Group type: EXPERIMENTAL
Intervention: Advice to remain active (AA)
Number of subjects: 538

Group type: EXPERIMENTAL
Intervention: Immediate physiotherapy (IP)
Number of subjects: 538

Group type: COMPARATOR
Intervention: Advice to rest (AR)
Number of subjects: 538

Group type: COMPARATOR
Intervention: Usual care physiotherapy (UCP)
Number of subjects: 538